Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re run­ning a cut­ting-edge, clin­i­cal-stage biotech, prob­a­bly pub­lic, but not nec­es­sar­i­ly so, which could see some big ad­van­tages team­ing up with some mar­quee re­searchers, pick­ing up say $50 mil­lion to $75 mil­lion dol­lars in a non-threat­en­ing mi­nor­i­ty eq­ui­ty in­vest­ment that could take you to the next lev­el.

Doug Gior­dano might have some thoughts on how that could work out.

The SVP of busi­ness de­vel­op­ment at the phar­ma gi­ant has helped forge a new fund called the Pfiz­er Break­through Growth Ini­tia­tive. And he has $500 mil­lion of Pfiz­er’s mon­ey to put be­hind 7 to 10 — or so — biotech stocks that fit that gen­er­al de­scrip­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.